Hiroyuki Fujimoto

Tokyo National Hospital

Papers

1

Total Citations

37

H-Index

1

About

Dr. Hiroyuki Fujimoto is a leading figure in urologic oncology, with a primary focus on bladder cancer clinical management and guideline development. His most significant contribution is his leadership in revising the Japanese Urological Association’s Clinical Practice Guidelines for Bladder Cancer, notably the 2019 edition, which has garnered 37 citations. This work reflects his commitment to standardizing and advancing clinical care in a rapidly evolving therapeutic landscape, addressing critical updates in diagnosis, treatment protocols, and surveillance strategies. Dr. Fujimoto’s expertise lies in bridging evidence-based medicine with practical, patient-centered urology, ensuring that Japanese and international practitioners have access to current, actionable recommendations. His role as a revision working position paper author underscores his influence in shaping national oncology policy and his dedication to improving outcomes for bladder cancer patients. Through his guideline work and ongoing research, Dr. Fujimoto continues to impact the field, providing a foundation for clinical decision-making and inspiring future urologists to prioritize rigorous, collaborative approaches to cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper
37 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Tokyo National Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago